Drug Trial Radar · NCT07229586
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 2, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Conditions
- Solid Tumor
Interventions
SHR-7367 InjectionDrug
SHR-7367 injection.
SHR-1316 InjectionDrug
SHR-1316 injection.
Paclitaxel for InjectionDrug
Paclitaxel for injection (Albumin Bound).
Gemcitabine Hydrochloride for InjectionDrug
Gemcitabine Hydrochloride for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1 (IB Period): Dose-limiting toxicity (DLT).Time frame: Up to 28 days.
- Stage 1 (IB Period): Adverse events (AEs).Time frame: About 1 year.
- Stage 1 (IB Period): Serious adverse events (SAEs).Time frame: About 1 year.
- Phase II: Investigator-assessed objective response rate (ORR).Time frame: Assessed every 6 weeks, about 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.